Introduction
============

With an extremely poor prognosis and low resection rate, pancreatic cancer (PC) ranks the fourth most common cause of cancer-related deaths in the United States, and the fifth in Europe.[@b1-ott-12-733] PC starts when a cell in the pancreas gains genetic changes, allowing it to grow uncontrollably. Surgical resection is the only curative strategy for PC. For patients with localized disease, radical surgery may offer long-term benefits.[@b2-ott-12-733] However, even in patients who undergo resection, the 5-year survival rate remains only 7%--24%, and the cumulative rate of recurrence remains up to 85%, indicating that surgery alone is typically inadequate.[@b3-ott-12-733],[@b4-ott-12-733]

For PC, the current standard of treatment is surgical resection with adjuvant chemotherapy.[@b5-ott-12-733],[@b6-ott-12-733] Some landmark experiments suggested the positive significance of adjuvant therapy.[@b7-ott-12-733],[@b8-ott-12-733] However, 20%--30% of patients failed to receive designated treatment due to postoperative complications, delayed recovery after surgery, patient rejection, comorbidities, or early disease recurrence, which is a major drawback of adjuvant therapy for PC.[@b5-ott-12-733],[@b7-ott-12-733],[@b9-ott-12-733] For borderline resectable PC, direct surgery may result in positive margins: R1 (microscopic margin) or R2 (positive margin). In recent years, neoadjuvant therapy (NAT) strategies have been increasingly employed for borderline resectable and resectable tumors.[@b10-ott-12-733]--[@b12-ott-12-733] Previous studies demonstrated that NAT might improve the R0 (negative margin) resection rate and improve prognosis in borderline resectable PC (RPC).[@b13-ott-12-733],[@b14-ott-12-733]

However, for RPC, no consensus has been achieved at present concerning whether it may improve the prognosis through NAT. Accordingly, we performed this study to compare the differences in overall survival (OS) time, R0 resection rate, and positive lymph nodes rate between patients who received NAT and those with upfront surgery.

Materials and methods
=====================

This meta-analysis followed the PRISMA guidelines.[@b15-ott-12-733]

Literature search
-----------------

The literature was reviewed systematically by searching PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials databases from inception until September 2018. The search strategy in PubMed included the following domains of Medical Subject Heading terms: "pancreatic neoplasm", "neoadjuvant", and "resectable". These terms were combined with "AND" or "OR", which were provided in [Table S2](#SD2-ott-12-733){ref-type="supplementary-material"} (supporting information). Searched documents were not subject to publication time limitations. Embase, Web of Science, and Cochrane Library searches were completed with the authors' own terminology.

Inclusion and exclusion criteria
--------------------------------

Studies included patients with RPC either treated by upfront surgery or NAT. Two authors independently assessed the included observational studies. Studies exclusion criteria were as follows: 1) patients without surgery were included in the study; 2) the study did not contain a control group; 3) for outcome indicators, the number of patients was unclear; and 4) the study included patients with marginally resectable or locally advanced PC.

Data extraction and quality assessment
--------------------------------------

Two authors independently evaluated the title and abstract of the primary selection and then conducted a full-text screening. Disagreements were resolved via discussion. R0 resection rate, positive lymph node rate, and survival data were extracted in each study. The HR and its 95% CI were extracted from the survival curve provided in the article with Engauge Digitizer 4.1 software (Markmitch, Boston, MA, USA).[@b16-ott-12-733]

Quality assessment of each article was performed using the Newcastle--Ottawa scale (NOS).[@b17-ott-12-733] The NOS allows for the evaluation of methods of patient selection, comparability of study groups, and reporting of important outcomes. Details are available in [Table S1](#SD1-ott-12-733){ref-type="supplementary-material"} (supporting information).

Statistical analyses
--------------------

Analyses were performed using STATA version 12.0 (Stata Corporation, College Station, TX, USA) software. All *P*-values were two sided, and *P*\<0.05 was regarded as significant. The results of individual studies were summarized. The estimates were calculated using fixed-effects or random-effects models according to the heterogeneity, which was reported using the Cochrane's *Q*-test[@b18-ott-12-733] and the inconsistency index value (I^2^).[@b19-ott-12-733] Publication bias was judged using funnel plot and Egger's test.

Results
=======

Characteristics of included studies
-----------------------------------

A total of eleven studies were included in the meta-analysis.[@b20-ott-12-733]--[@b30-ott-12-733] The characteristics of the patients who received NAT and upfront surgery are presented in [Tables 1](#t1-ott-12-733){ref-type="table"} and [2](#t2-ott-12-733){ref-type="table"}, respectively. The upfront surgery group was regarded as the control group. [Figure 1](#f1-ott-12-733){ref-type="fig"} presents the flowchart of the literature search and selection process. Age was the only available risk factor among the patients involved. However, no significant difference in age was observed between the NAT group and the upfront surgery group. The results of NOS analysis indicated that the studies we have included were of high quality.

Meta-analysis results
---------------------

The main results of our meta-analysis are presented in [Table 3](#t3-ott-12-733){ref-type="table"}. Eleven studies involving 9,388 patients were assessed in the comparison of the R0 resection rate. As indicated in [Figure 2](#f2-ott-12-733){ref-type="fig"}, patients receiving NAT before surgery had a better R0 resection rate compared with patients receiving upfront surgery (nine trials; 9,388 patients; OR=1.89; 95% CI=1.26--2.83), especially in the gemcitabine (Gem)-based + RT group (four trials; 757 patients; OR=3.59; 95% CI=2.08--6.21). In the 5-fluorouracil (5-Fu)-based + RT group, the NAT group did not exhibit an obvious advantage (three trials; 487 patients; OR=1.36; 95% CI=0.67--2.75). In the neoadjuvant chemotherapy (NCT) group, patients receiving chemotherapy had a higher R0 resection rate (two trials; 8,144 patients; OR=1.50; 95% CI=1.32--1.71).

Regarding the positive lymph node rate ([Figure 3](#f3-ott-12-733){ref-type="fig"}), the NAT group exhibited a remarkably reduced rate compared with the upfront surgery group (eleven trials; 9,386 patients; OR=0.34; 95% CI=0.31--0.37). In the subgroup analysis for positive lymph nodes, the Gem-based + RT group (five trials; 803 patients; OR=0.34; 95% CI=0.25--0.47), 5-Fu-based + RT group (four trials; 529 patients; OR=0.22; 95% CI=0.14--0.33), and the NCT group (two trials; 8,054 patients; OR=0.35; 95% CI=0.31--0.38) were associated with lower positive lymph node rates.

In the eleven studies included above, a total of seven studies (seven trials; 1,012 patients) provided either survival curves or HR and its 95% CI. The HR sum of survival for NAT compared with the upfront surgery group with a pooled HR of 0.91 (95% CI=0.79--1.05) indicated no significant survival advantage for NAT. In the subgroup analysis for OS time ([Figure 4](#f4-ott-12-733){ref-type="fig"}), the Gem-based + RT group (three trials; 280 patients; HR=0.88; 95% CI=0.69--1.12) and the 5-Fu-based + RT group (four trials; 738 patients; HR=0.93; 95% CI=0.78--1.11) consistently exhibited insignificant advantages in OS time.

Test of heterogeneity
---------------------

For the comparison of the R0 resection rate, moderate heterogeneity was observed. However, heterogeneity decreased when subgroup analyses were conducted based on neoadjuvant treatment methods. In addition, no significant heterogeneity was observed in overall and subgroup comparisons for positive lymph node rate analysis and OS analysis.

Sensitivity analysis
--------------------

Sensitivity analysis was utilized to detect the influence of each study by repeating the meta-analysis while omitting one study each time. [Figures 5A](#f5-ott-12-733){ref-type="fig"} and [6A](#f6-ott-12-733){ref-type="fig"} revealed that the results were reliable given that no individual study affected the pooled OR or HR significantly.

Publication bias
----------------

[Figure 5B](#f5-ott-12-733){ref-type="fig"} indicates that no significant publication bias for the R0 resection rate was observed, and this finding was confirmed by Egger's test (*P*=0.346). Moreover, the positive lymph node rate ([Figure 7](#f7-ott-12-733){ref-type="fig"}) did not exhibit publication bias (Egger's test: *P*=0.122). For the OS time comparison ([Figure 6B](#f6-ott-12-733){ref-type="fig"}), no significant publication bias was detected (Egger's test: *P*=0.707).

Discussion
==========

PC is classified as resectable, marginally resectable, or locally advanced.[@b31-ott-12-733],[@b32-ott-12-733] However, to date, the only potentially curative technique for managing PC is surgical resection with radiotherapy and/or chemotherapy regimens, which may improve disease-free and OS time.[@b33-ott-12-733] At present, NAT is increasingly used in various types of PCs given its benefits for vascularization improvement, early treatment of micrometastasis, and potential downgrading effect on borderline resectable PC.[@b34-ott-12-733]

Some previous analyses of PC revealed that patients receiving NAT exhibited a longer survival time.[@b35-ott-12-733],[@b36-ott-12-733] However, most of these studies only analyzed marginal resectable or locally advanced PC, which exhibited a poor prognosis if only upfront surgery treatment was administered. NAT is considered safe for resectable PC,[@b37-ott-12-733] and neoadjuvant therapy with multiple drugs is usually superior to monotherapy.[@b38-ott-12-733] Thus, new adjuvant therapies are increasingly being applied for RPC. The transition from upfront surgical to a systemic approach in the form of NAT is being investigated for the treatment of RPC.[@b39-ott-12-733],[@b40-ott-12-733] The driving force behind this shift is the growing recognition of the systematic early origins of the disease.[@b41-ott-12-733] However, previous studies on NAT for RPC were limited, and the results were inconclusive. For example, one study reported no difference in OS time between the NAT group and the upfront surgery group.[@b42-ott-12-733] However, some studies demonstrated that the survival rate of the NAT group was significantly improved compared with the upfront surgery group.[@b21-ott-12-733],[@b30-ott-12-733]

Meta-analysis can provide more reliable results compared with a single study and serves as a powerful tool to explain controversial conclusions. For this reason, we performed a meta-analysis to clarify whether NAT has significant benefits for RPC compared with upfront surgery. This meta-analysis was not the first meta-analysis that focused on the effect of NAT on RPC. However, we included newer and higher-quality studies and obtained a larger sample size to arrive at a more accurate conclusion. As a result, the comparative analysis between the NAT group and upfront surgery group revealed that NAT played a positive role on R0 resection rate and positive lymph node rate. This finding was consistent with our expectations.[@b35-ott-12-733],[@b43-ott-12-733] However, the benefits of NAT for OS time were statistically insignificant. In the studies we included, 73.6% of the patients who were judged resectable were resected after NAT. This rate was similar to published resection rates of 78%--96%.[@b44-ott-12-733]

Currently, various NAT methods have been used in clinical practice.[@b20-ott-12-733]--[@b30-ott-12-733] Most studies supported the use of Gem or 5-Fu in the neoadjuvant setting. In fact, different neoadjuvant settings may lead to different clinical outcomes, suggesting that the prognostic indicators of PC can vary notably due to methodological differences. As a result, stratified analysis was performed based on neoadjuvant therapy methods. Regarding the R0 resection rate, the NCT group without radiation therapy also had a higher R0 resection rate, indicating the significant role of chemotherapy drugs in resectable PC. In fact, for resectable PC, neoadjuvant radiotherapy has often been used in conjunction with chemotherapy to improve marginal negative resection rates.[@b45-ott-12-733] In the subgroup analysis with radiation therapy, the Gem-based + RT group exhibited more advantages compared with the 5-Fu-based + RT group. There are several possible mechanisms to explain this result. First, Gem has potent radiosensitizing properties that are critical in a disease with a propensity for positive surgical margins and local recurrence.[@b46-ott-12-733] Second, compared with 5-Fu, the use of Gem as a radiosensitizer generates greater tumor cell killing. Moreover, Gem provides superior systemic treatment of micrometastases.[@b10-ott-12-733]

After surgical resection, \~80% of patients exhibited a potential risk of extrapancreatic metastasis and required adjuvant therapy. Indeed, the surgical approach and postoperative recovery process may lead to a delayed or reduced dose of radiotherapy and chemotherapy, thus objectively delaying adjuvant therapy. Previous studies demonstrated that NAT may lead to a more favorable regression of lymph node metastasis compared with adjuvant therapy.[@b47-ott-12-733] At the time of surgery, patients who received NAT had smaller tumor sizes. Although the specific mechanism is unclear, the positive lymph node rate was significantly reduced in the NAT group in most studies.[@b20-ott-12-733],[@b21-ott-12-733],[@b23-ott-12-733] The results of our study were consistent with previous studies, which further showed that NAT played an important role in positive lymph nodes. For RPC, neoadjuvant chemoradiation may exhibit a reduced positive lymph node rate compared with neoadjuvant chemotherapy, and the addition of radiation therapy may improve the quality of NAT.[@b48-ott-12-733] However, further studies are needed to determine whether the difference is statistically significant. Moreover, the addition of radiotherapy may increase costs.[@b48-ott-12-733]

Overall, survival time is one of the most prognostic indicators for survival in RPC patients. Differences in neo-adjuvant settings exhibit different impacts on prognosis. Finally, the results of our meta-analysis for RPC demonstrated similar OS values for the Gem-based + RT group and 5-Fu-based + RT group compared to the upfront surgery group. These effects may be attributed to several possible mechanisms. First, compared with marginal resectable or locally advanced PC, RPC exhibits better tissue and cell characteristics, which may explain why NAT did not have significant benefits for RPC. In addition, patients exclusively treated with upfront surgery generally received additional adjuvant therapy at a later date. However, a small number of patients refused to receive adjuvant therapy or terminated it ahead of schedule for various reasons, which may make the associations unreliable.

Furthermore, despite the overall robust statistical evidence generated through this analysis, some limitations have been identified. First, among the studies we included, only three studies were randomized controlled trials with a total of 165 patients. Currently, the number of completed RCT is insufficient, which may be due to the slow recruitment of patients and patient choice. Moreover, it is difficult for multicenter experimental institutions to reach a unified opinion given the diversity of neoadjuvant treatment options. As a result, the small number of RCT studies is inevitable to some extent. Therefore, more studies are required to provide more clear conclusions. Second, in addition to age, other information about the included population, such as gender and lifestyle, was not available in most studies. Moreover, as a multifactorial disease, PC results from a combination of various complicated factors, including a variety of genetic and environmental factors. Therefore, if all patient data had been available, the results would have been more accurate.

Conclusion
==========

The results of the present meta-analysis suggested that NAT can increase the R0 resection rate and decrease the positive lymph node rate. However, patients receiving NAT exhibited comparable survival as patients receiving upfront surgery. These results indicate that NAT offers insignificant advantages for postoperative survival. Although upfront surgery continues to be the standard and only curative treatment option for RPC, the results of this meta-analysis demonstrate the increasing use of NAT with some favorable outcomes. Numerous RCT studies are ongoing, for example, the NCT01372735.[@b49-ott-12-733] These studies focus on RPC and its prognosis after receiving NAT. We believe that when these studies are completed, we will draw more accurate conclusions after analyzing their data.

Supplementary materials
=======================

###### 

Newcastle--Ottawa scale (NOS)

  Reference                                Is the case definition adequate?   Representativeness of the cases   Selection of controls   Definition of controls   Comparability of cases and controls on the basis of the design or analysis   Ascertainment of exposure   Same method of ascertainment for cases and controls   Nonresponse rate   Total scores
  ---------------------------------------- ---------------------------------- --------------------------------- ----------------------- ------------------------ ---------------------------------------------------------------------------- --------------------------- ----------------------------------------------------- ------------------ --------------
  Barbier et al 2011[@b50-ott-12-733]      ⋆                                  ⋆                                 ⋆                       ⋆                        ⋆                                                                            ⋆                           ⋆                                                     ☆                  7
  Casadei et al 2015[@b51-ott-12-733]      ⋆                                  ⋆                                 ⋆                       ⋆                        ⋆⋆                                                                           ⋆                           ☆                                                     ☆                  7
  Papalezova et al 2012[@b52-ott-12-733]   ⋆                                  ☆                                 ⋆                       ⋆                        ⋆⋆                                                                           ☆                           ⋆                                                     ☆                  6
  Golcher et al 2015[@b53-ott-12-733]      ⋆                                  ⋆                                 ☆                       ⋆                        ⋆⋆                                                                           ⋆                           ⋆                                                     ⋆                  8
  Mokdad et al 2017[@b54-ott-12-733]       ⋆                                  ☆                                 ⋆                       ⋆                        ⋆⋆                                                                           ⋆                           ⋆                                                     ⋆                  8
  Moutardier et al 2004[@b55-ott-12-733]   ⋆                                  ⋆                                 ⋆                       ⋆                        ⋆⋆                                                                           ☆                           ⋆                                                     ☆                  7
  Vento et al 2007[@b56-ott-12-733]        ⋆                                  ⋆                                 ☆                       ⋆                        ⋆⋆                                                                           ⋆                           ⋆                                                     ☆                  7
  Tajima et al 2012[@b57-ott-12-733]       ⋆                                  ⋆                                 ☆                       ⋆                        ⋆⋆                                                                           ☆                           ⋆                                                     ☆                  6
  Motoi et al 2014[@b58-ott-12-733]        ⋆                                  ⋆                                                         ⋆                        ⋆⋆                                                                           ⋆                           ⋆                                                     ☆                  7
  Fujii et al 2017[@b59-ott-12-733]        ⋆                                  ⋆                                 ⋆                       ⋆                        ⋆⋆                                                                           ☆                           ⋆                                                     ☆                  7
  Tzeng et al 2014[@b60-ott-12-733]        ⋆                                  ⋆                                 ⋆                       ⋆                        ⋆⋆                                                                           ☆                           ⋆                                                     ☆                  7

**Notes:** ⋆, Get one point; ☆, get no point.

###### 

Search strategy

  -------------------------------------------------------------------------------------------
  PubMed: ((pancreatic neoplasm) OR (pancreatic cancer)) AND (neoadjuvant) AND (resectable)
  Embase: (pancreatic) AND (resectable) AND (neoadjuvant)
  Web of Science: (pancreatic) AND (resectable) AND (neoadjuvant)
  Cochrane Library: (pancreatic) AND (resectable) AND (neoadjuvant)
  -------------------------------------------------------------------------------------------
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![Flow diagram of literature search and selection process.](ott-12-733Fig1){#f1-ott-12-733}

![Forest plots of R0 resection rate.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** 5-Fu, 5-fluorouracil; Gem, gemcitabine; NCT, neoadjuvant chemotherapy; RT, radiation therapy.](ott-12-733Fig2){#f2-ott-12-733}

![Forest plots of positive lymph nodes.\
**Abbreviations:** 5-Fu, 5-fluorouracil; Gem, gemcitabine; NCT, neoadjuvant chemotherapy; OS, overall survival; RT, radiation therapy.](ott-12-733Fig3){#f3-ott-12-733}

![Forest plots of OS time.\
**Abbreviations:** 5-Fu, 5-fluorouracil; Gem, gemcitabine; OS, overall survival; RT, radiation therapy.](ott-12-733Fig4){#f4-ott-12-733}

![Sensitivity analysis and funnel plot of the R0 resection rate.\
**Notes:** (**A**) Sensitivity analysis of the R0 resection rate. (**B**) Funnel plot of the R0 resection rate.](ott-12-733Fig5){#f5-ott-12-733}

![Sensitivity analysis and funnel plot of OS.\
**Notes:** (**A**) Sensitivity analysis of OS. (**B**) Funnel plot of OS. **Abbreviation:** OS, overall survival.](ott-12-733Fig6){#f6-ott-12-733}

![Egger's funnel plot for publication bias test of positive lymph nodes.](ott-12-733Fig7){#f7-ott-12-733}

###### 

Characteristics of the neoadjuvant treatment group included in the meta-analysis

  Reference                           Year   No. of patients   Median age (years)   Regimen                                       Median OS (months)   Resection rate ITT (%)   R0 rate (%)   Patients with positive lymph nodes (%)   Quality score
  ----------------------------------- ------ ----------------- -------------------- --------------------------------------------- -------------------- ------------------------ ------------- ---------------------------------------- ---------------
  Fujii et al[@b20-ott-12-733]        2017   40                65                   5-Fu + oteracil and gimeracil + S-1 + RT      24.9                 90                       86            39                                       7
  Mokdad et al[@b21-ott-12-733]       2017   2,005             64                   CT                                            26                   NM                       83            48                                       8
  Casadei et al[@b22-ott-12-733]      2015   18                71.5                 Gem 6 weeks + (Gem + RT) 6 weeks              NM                   61                       64            55                                       7
  Golcher et al[@b23-ott-12-733]      2015   33                62.5                 Gem + Cis + RT (55.8 Gy)                      25                   58                       90            32                                       8
  Tzeng et al[@b24-ott-12-733]        2014   115               65.5                 Gem + Cis + RT                                28                   82.6                     89.4          51.6                                     7
  Motoi et al[@b25-ott-12-733]        2014   185               68                   Gem/S-1/Gem + S-1/ other/+ RT (35.2--54 Gy)   NM                   92.4                     95.9          30.6                                     7
  Papalezova et al[@b26-ott-12-733]   2012   144               64                   5-Fu + RT (30--50.4 Gy)                       20                   52                       78            25                                       6
  Tajima et al[@b27-ott-12-733]       2012   13                62.6                 Gem + S-1                                     NM                   NM                       84.6          76.9                                     6
  Barbier et al[@b28-ott-12-733]      2011   88                65                   5-Fu + Cis + RT (45 Gy)                       17                   43                       74            29                                       7
  Vento et al[@b29-ott-12-733]        2007   22                65                   Gem + RT (50.4 Gy)                            30.2                 NM                       NM            32                                       7
  Moutardier et al[@b30-ott-12-733]   2004   39                65                   5-Fu + Cis + RT                               13.7                 58                       NM            13                                       7

**Abbreviations:** Cis, cisplatin; 5-Fu, 5-fluorouracil; Gem, gemcitabine; ITT, intention to treat; NM, not mention; OS, overall survival; RT, radiation therapy; S-1, S-1Meiji Combination Capsules T20/T25; CT, chemotherapy.

###### 

Characteristics of the preoperative group included in the meta-analysis

  Reference                           Year   No. of patients   Median age (years)   Median OS (months)   Resection rate ITT (%)   R0 rate (%)   Patients with positive lymph nodes (%)
  ----------------------------------- ------ ----------------- -------------------- -------------------- ------------------------ ------------- ----------------------------------------
  Fujii et al[@b20-ott-12-733]        2017   233               67                   23.5                 88                       70            71
  Mokdad et al[@b21-ott-12-733]       2017   6,015             65                   23                   NM                       76            74
  Casadei et al[@b22-ott-12-733]      2015   20                67.5                 NM                   75                       33            87
  Golcher et al[@b23-ott-12-733]      2015   33                65.1                 18.9                 70                       70            57
  Tzeng et al[@b24-ott-12-733]        2014   52                61.9                 25.3                 92.3                     81.2          81
  Motoi et al[@b25-ott-12-733]        2014   397               68                   NM                   94.5                     81.3          55.2
  Papalezova et al[@b26-ott-12-733]   2012   92                65                   17                   74                       79            62
  Tajima et al[@b27-ott-12-733]       2012   21                66                   NM                   NM                       85.7          54.1
  Barbier et al[@b28-ott-12-733]      2011   85                64                   15                   79                       67            64
  Vento et al[@b29-ott-12-733]        2007   25                63                   35.9                 NM                       NM            44
  Moutardier et al[@b30-ott-12-733]   2004   17                65                   26.6                 100                      NM            65

**Abbreviations:** ITT, intention to treat; NM, not mention; OS, overall survival.

###### 

Meta-analysis results of noeadjuvant treatment for resectable pancreatic cancer

  Group                      N[a](#tfn3-ott-12-733){ref-type="table-fn"}   Neoadjuvant[b](#tfn4-ott-12-733){ref-type="table-fn"}   Surgery first[c](#tfn5-ott-12-733){ref-type="table-fn"}   OR (95% CI)[d](#tfn6-ott-12-733){ref-type="table-fn"}   *P*-value[e](#tfn7-ott-12-733){ref-type="table-fn"}   HR (95% CI)[d](#tfn6-ott-12-733){ref-type="table-fn"}   *P*-value[e](#tfn7-ott-12-733){ref-type="table-fn"}
  -------------------------- --------------------------------------------- ------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------
  **R0 resection rate**                                                                                                                                                                                                                                                                                                                                            
  Gem based + RT             4                                             296                                                     461                                                       3.59 (2.08--6.21)                                       0.468                                                 --                                                      --
  5-Fu based + RT            3                                             150                                                     337                                                       1.36 (0.67--2.75)                                       0.159                                                 --                                                      --
  CT                         2                                             2,018                                                   6,126                                                     1.50 (1.32--1.71)                                       0.616                                                 --                                                      --
  Total                      9                                             2,464                                                   6,924                                                     1.89 (1.26--2.83)                                       0.042                                                 --                                                      --
  **Positive lymph nodes**                                                                                                                                                                                                                                                                                                                                         
  Gem based + RT             5                                             317                                                     486                                                       0.34 (0.25--0.47)                                       0.757                                                 --                                                      --
  5-Fu based + RT            4                                             173                                                     356                                                       0.22 (0.14--0.33)                                       0.617                                                 --                                                      --
  CT                         2                                             2,018                                                   6,036                                                     0.35 (0.31--0.38)                                       0.281                                                 --                                                      --
  Total                      11                                            2,508                                                   6,878                                                     0.34 (0.31--0.37)                                       0.610                                                 --                                                      --
  **Overall survival**                                                                                                                                                                                                                                                                                                                                             
  Gem based + RT             3                                             170                                                     110                                                       --                                                      --                                                    0.88 (0.69--1.12)                                       0.531
  5-Fu based + RT            4                                             311                                                     427                                                       --                                                      --                                                    0.93 (0.78--1.11)                                       0.324
  Total                      7                                             481                                                     531                                                       --                                                      --                                                    0.91 (0.79--1.05)                                       0.561

**Notes:**

Number of studies.

Number of patients receiving neoadjuvant treatment.

Number of patients receiving surgery first.

Random-effects model was used when *P*-value for heterogeneity test \<0.1; otherwise, fixed-effects model was used.

*P*-value of *Q* test for heterogeneity.

**Abbreviations:** 5-Fu, 5-fluorouracil; Gem, gemcitabine; RT, radiation therapy; CT, chemotherapy.
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